10-Q: HeartSciences Inc. Reports Q2 2025 Results, Focuses on FDA Submission and AI-ECG Development

HeartSciences Inc. released its second quarter 2025 results, highlighting ongoing efforts towards FDA submission for its MyoVista wav ECG device and the development of AI-ECG algorithms.

Summary

• HeartSciences Inc. reported a net loss of $4.1 million for the six months ended October 31, 2024, compared to a net loss of $3.1 million for the same period in 2023.
• The company's operating expenses increased to $4.1 million for the six months ended October 31, 2024, up from $2.9 million in the prior year, driven by higher research and development costs.
• Research and development expenses rose to $2.4 million for the six months ended October 31, 2024, a significant increase from $1.3 million in the same period of 2023, due to consulting costs for the MyoVista Insights Cloud Platform and increased headcount.
• The company's cash and cash equivalents decreased to $4.1 million as of October 31, 2024, from $5.8 million as of April 30, 2024.
• HeartSciences is preparing for a 510(k) FDA submission for its MyoVista wav ECG device, aiming for the first calendar quarter of 2025.
• The company is also developing a cloud-based platform, the MyoVista Insights Cloud Platform, and plans to submit it for FDA clearance in the second half of 2025.
• The company has been adjusting its AI-ECG algorithm to reflect updated echo measurement thresholds in respect of 60-year-old patients.
• The company has an accumulated deficit of $71.5 million as of October 31, 2024.
• The company has raised approximately $9.8 million through an at-the-market (ATM) facility and $1.7 million through an equity line.

Sentiment

Score: 4

Explanation: The document highlights significant progress in product development and strategic partnerships, but the company's financial situation and going concern issues temper the overall sentiment. The company is making progress but is still in a high risk phase.

Positives

• The company is actively progressing towards FDA submission for its key products.
• The company has secured additional funding through an equity line, an ATM facility and a note purchase agreement.
• The company is developing a cloud-based platform to host AI-ECG algorithms, which could expand its market reach.
• The company is collaborating with Mount Sinai to commercialize a range of AI-ECG algorithms.
• The company has been granted a patent from the Indian Patent Office covering MyoVista wavelet technology.
• The company has been granted a patent allowance from the United States Patent and Trademark Office for the detection of left ventricular and/or right ventricular dysfunction using deep learning.

Negatives

• The company has incurred significant losses and negative cash flows since its inception.
• The company's cash reserves have decreased significantly.
• The company's accumulated deficit has increased to $71.5 million.
• The company's existing cash is insufficient to fund operations for the next twelve months.
• The company's disclosure controls and procedures were not effective as of October 31, 2024 due to identified material weaknesses.
• The company is dependent on obtaining additional funding to continue operations and achieve FDA clearance.

Risks

• The company's ability to continue as a going concern is in doubt due to its financial condition.
• The company's success is dependent on receiving FDA clearances for its products.
• The company may not be able to secure additional funding on acceptable terms.
• The company faces competition from larger companies and other technologies.
• The company's internal controls over financial reporting have material weaknesses.
• The company is subject to risks associated with the development of a commercial market.

Future Outlook

The company plans to submit its MyoVista wav ECG device for FDA clearance in the first calendar quarter of 2025 and the MyoVista Insights Cloud Platform in the second half of 2025. The company expects to continue to invest in research and development and will need to raise additional capital to support its operations.

Management Comments

• Management believes that current resources would be insufficient to fund operations for the next twelve months following the issuance of these financial statements.
• Management's plans include raising capital through the sale of additional equity securities, debt, or capital inflows from strategic partnerships.
• Management can provide no assurance that such financing or strategic relationships will be available on acceptable terms, or at all.

Industry Context

The company is operating in the medical technology sector, specifically focusing on cardiovascular diagnostics. The company aims to improve the clinical usefulness of ECGs by incorporating AI-based technology. The company's products are intended to address the limitations of conventional ECGs in detecting structural and ischemic heart disease.

Comparison to Industry Standards

• The company's focus on AI-ECG algorithms aligns with the growing trend of incorporating artificial intelligence in medical diagnostics.
• The company's development of a cloud-based platform is consistent with the industry's move towards digital health solutions.
• The company's financial performance is typical of early-stage medical technology companies that are heavily investing in research and development.
• The company's reliance on external funding is common in the medical device industry, particularly for companies seeking regulatory approvals.
• The company's collaboration with Mount Sinai is similar to other partnerships between medical technology companies and research institutions.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment due to the company's financial condition.
• Employees may be concerned about the company's ability to continue operations and maintain employment.
• Customers and partners may be concerned about the company's ability to bring its products to market.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to submit its MyoVista wav ECG device for FDA clearance in the first calendar quarter of 2025.
• The company plans to submit its MyoVista Insights Cloud Platform for FDA clearance in the second half of 2025.
• The company will continue to invest in research and development.
• The company will seek additional funding through equity, debt, or strategic partnerships.

Key Dates

Keywords

AI-ECG, MyoVista wav ECG, FDA clearance, cardiac dysfunction, electrocardiograph, medical device, cloud platform, 510(k), diastolic dysfunction, systolic dysfunction